EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Deubiquitinase inhibitors: from evolving concepts to preclinical evaluation

Gunter Maubach, Lois Hamann, Matthias Stein, Edgar Haak, Michael Naumann

Drug Discovery Today · 2026

DOI: 10.1016/j.drudis.2026.104751 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Discovery Today, 2026. Verfasst von Gunter Maubach und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Experimental Internal Medicine, Otto von Guericke University Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, Germany. Electronic addre…. Hauptthemen laut MEDLINE: Deubiquitinating Enzymes, Enzyme Inhibitors. Die Arbeit nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation, Max Planck Foundation, Sachsen-Anhalt Ministerium fur Wirtschaft Wissenschaft und Digitalisierung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Deubiquitinases (DUBs) regulate substrate ubiquitination, thereby modulating signal transduction, trafficking, and proteasomal degradation. They have emerged as promising therapeutic targets owing to their involvement in a variety of pathological conditions. However, the limited availability of DUB inhibitors with adequate specificity, safety, and efficacy remains a major barrier to successful clinical translation. Recent studies indicate that exploring both allosteric and covalent inhibition strategies together with integrated computational workflows could address this gap. In this review, we summarize current developments concerning the chemistry of small-molecule DUB inhibitors, improved computational discovery workflows, and the preclinical evaluation of candidate compounds.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Deubiquitinating EnzymesEnzyme InhibitorsHumansAnimalsDrug DiscoveryDrug Evaluation, PreclinicalUbiquitination

Stichwörter der Autor:innen

computer-aided toolsdrug developmentsmall-molecule inhibitorsubiquitin

Substanzen

Deubiquitinating EnzymesEnzyme Inhibitors

Autor:innen und Institutionen

  • Institute of Experimental Internal Medicine, Otto von Guericke University Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, Germany. Electronic address: gunter.maubach@med.ovgu.de.
  • Institute of Chemistry, Otto-von-Guericke-University Magdeburg, Universitätsplatz 2, 39106 Magdeburg, Germany.
  • Max Planck Institute for Dynamics of Complex Technical Systems, Molecular Simulations and Design Group, Sandtorstrasse 1, 39106 Magdeburg, Germany.
  • Institute of Experimental Internal Medicine, Otto von Guericke University Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, Germany.

Förderung

  • German Research Foundation
  • Max Planck Foundation
  • Sachsen-Anhalt Ministerium fur Wirtschaft Wissenschaft und Digitalisierung

Zitieren

APA

Maubach, G., Hamann, L., Stein, M., Haak, E., & Naumann, M. (2026). Deubiquitinase inhibitors: from evolving concepts to preclinical evaluation. Drug Discovery Today. https://doi.org/10.1016/j.drudis.2026.104751

Vancouver

Maubach G, Hamann L, Stein M, Haak E, Naumann M. Deubiquitinase inhibitors: from evolving concepts to preclinical evaluation. Drug Discovery Today. 2026. doi:10.1016/j.drudis.2026.104751

BibTeX
@article{Maubach2026,
  author = {Maubach, Gunter and Hamann, Lois and Stein, Matthias and Haak, Edgar and Naumann, Michael},
  title = {Deubiquitinase inhibitors: from evolving concepts to preclinical evaluation},
  journal = {Drug Discovery Today},
  year = {2026},
  doi = {10.1016/j.drudis.2026.104751}
}
Kostenlos starten →